Integrating Network Pharmacology to Explore the Pharmacology Mechanisms of Meliae Cortex Against Hepatocellular Carcinoma
DOI:
https://doi.org/10.53469/jcmp.2024.06(06).24Keywords:
Meliae Cortex, Hepatocellular Carcinoma, Network PharmacologyAbstract
Objective: Using network pharmacology to study the active ingredients and mechanism of action of Meliae Cortex in the treatment of Hepatocellular Carcinoma, providing theoretical basis for clinical application. Methods: Applying the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) to obtain the active ingredients and targets of Meliae Cortex, Using Genecard (https://genecard, org/) database and Online Mendelian Inheritance in Man (OMIM) database (http://omim. org/), select " Hepatocellular Carcinoma " as the keyword to search for disease targets of Hepatocellular Carcinoma, After obtaining the intersection targets of Melia azedarach and Hepatocellular Carcinoma using Venny, a common target visualization network diagram was constructed using STRING database and Cytoscape. Realize gene (GO) enrichment analysis and (KEGG) enrichment analysis using the metascape database and microbiome platform. Results: Obtained 15 active ingredients from Meliae Cortex, 5024 Hepatocellular Carcinoma targets, and 32 common targets. GO analysis shows that biological processes mainly involve the regulation of responses to steroid hormones, estradiol, organic compounds, and various chemical and physical stimuli; KEGG enrichment shows that anti-cancer effects are mainly exerted through pathways such as AGE-RAGE and TNF. Conclusion: Using network pharmacology methods, it has been demonstrated that Meliae Cortex exerts therapeutic effects on Hepatocellular Carcinoma through multiple components, targets, and pathways, providing a theoretical basis for clinical application.
References
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
Chen W, Zheng R Baade PD, et al. Cancer staistics in China, 2015[J].CA Cancer J Clin, 2016,66(2):115-132.
Jianlou Z, Xiuhui Z. Pharmacological effects and clinical applications of Melia azedarach bark and its main pharmacological components[J]. Journal of Traditional Chinese Veterinary Medicine, 2007(2):65-66.
Zeng L, Gu Z M, Fang X P, et al. Two new bioactive triterpenoids from Melia volkensii[J]. Tetrahedron, 2011, 51(9): 2477 -2488
Y.L. Shi, F. Mu, Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine, Prog[J]. Neurobiol, 2017, 82: 1-10.
Q. Wang, Z. Wang, G.L. Hou, P. Huang, Toosendanin suppresses glioma progression property and induces apoptosis by regulating miR-608/Notch axis, Cancer Manag. Res. 12 (2020) 3419–3431.
H.H. Wang, C.Y. Wen, S.Y. Chen, F. Wang, L. He, W.Q. Li, et al., Toosendanin- induced apoptosis in colorectal cancer cells is associated with the κ-opioid receptor/β-catenin signaling axis, Biochem. Pharmacol. 177 (2020) 114014.
T. Gao, A. Xie, X.Q. Liu, H.B. Zhan, J. Zeng, M. Dai, et al., Toosendanin induces the apoptosis of human Ewing's sarcoma cells via the mitochondrial apoptotic pathway, Mol. Med. Rep. 20 (2019) 135–140.
S.L. Shao, S.S. Li, C. Liu, W.W. Zhang, Z.Z. Zhang, S.W. Zhu, et al., Toosendanin induces apoptosis of MKN-45 human gastric cancer cells partly through miR-23a- 3p-meidated downregualtion of BCL2, Mol. Med. Rep. 22 (2020) 1793–1802.
S. Zhang, L. Cao, Z.R. Wang, Z. Li, J. Ma, Anti-cancer effect of toosendanin and its underlying mechanisms, J. Asian Nat. Prod. Res. 21 (2019) 270–283.
Z. Pei, W. Fu, G.P. Wang, A natural product toosendanin inhibits epithelial- mesenchymal transition and tumor growth in pancreatic cancer via deactivating Akt/mTOR signaling, Biochem. Biophys. Res. Commun. 493 (2017) 455–460].
Z. Pei, W. Fu, G.P. Wang, A natural product toosendanin inhibits epithelial mesenchymal transition and tumor growth in pancreatic cancer via deactivating Akt/mTOR signaling, Biochem. Biophys. Res. Commun. 493 (2017) 455–460.
hang J, Yang F, Mei X, Yang R, Lu B, Wang Z, Ji L. Toosendanin and isotoosendanin suppress triple-negative breast cancer growth via inducing necrosis, apoptosis and autophagy. Chem Biol Interact. 2022 Jan 5;351:109739.
Chen Y, Yang Y, Wang N, Liu R, Wu Q, Pei H, Li W. β-Sitosterol suppresses hepatocellular carcinoma growth and metastasis via FOXM1-regulated Wnt/β-catenin pathway. J Cell Mol Med. 2024 Feb;28(3):e18072.
Huo R, Yang WJ, Liu Y, Liu T, Li T, Wang CY, Pan BS, Wang BL, Guo W. Stigmasterol: Remodeling gut microbiota and suppressing tumor growth through Treg and CD8+ T cells in hepatocellular carcinoma. Phytomedicine. 2023 Nov 25;129:155225.
Lin XM, Li S, Zhou C, Li RZ, Wang H, Luo W, Huang YS, Chen LK, Cai JL, Wang TX, Zhang QH, Cao H, Wu XP. Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer. Int J Biochem Cell Biol. 2019 Nov;116:105610.
Jia Y, Yan Q, Zheng Y, Li L, Zhang B, Chang Z, Wang Z, Tang H, Qin Y, Guan XY. Long non-coding RNA NEAT1 mediated RPRD1B stability facilitates fatty acid metabolism and lymph node metastasis via c-Jun/c-Fos/SREBP1 axis in gastric cancer. J Exp Clin Cancer Res. 2022 Sep 29;41(1):287.
Bhat AA, Thapa R, Afzal O, Agrawal N, Almalki WH, Kazmi I, Alzarea SI, Altamimi ASA, Prasher P, Singh SK, Dua K, Gupta G. The pyroptotic role of Caspase-3/GSDME signalling pathway among various cancer: A Review. Int J Biol Macromol. 2023 Jul 1;242(Pt 2):124832.
Waghela BN, Vaidya FU, Ranjan K, Chhipa AS, Tiwari BS, Pathak C. AGE-RAGE synergy influences programmed cell death signaling to promote cancer. Mol Cell Biochem. 2021 Feb;476(2):585-598.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Zhiyun Zhang, Jiequn Ma, Suoni Li, Qian Ge, Zheng Zhao
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
